Conference Overview

The Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, along with the Federation of Indian Chambers of Commerce & Industry (FICCI) has been actively working towards growth of Pharma & Medical Device sector.

Since the objective has always been to encourage and bring forward best technology solutions and manufacturing, therefore, Department of Pharmaceuticals announced India Pharma & India Medical Device series of events which is an annual activity.

INDIA PHARMA-2023 brings you an immense opportunity:

  • To be a part of the scientific acceleration
  • To meet world class personalities, young leaders of Pharma Industry and scholars.
  • Scientific delegates and young scientists to join this conference to utilize the expertise and novelties that brings a new era for innovations in the field of Pharmacy, which brings well versed scrutinizers at one place.
  • It provides a platform to have open discussions and knowledge sharing with field experts at INDIA PHARMA-2022.

Pharma Sector Overview

The Indian pharmaceutical industry ranks third globally in pharmaceutical production by volume and is known for its generic medicines and low-cost vaccines. The total annual turnover of Pharmaceuticals in the fiscal year 2021-22 was Rs. 3,44,125 crore (USD 42.34 Bn). Major segments of Indian Pharmaceutical Industry include generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics. Indian pharmaceutical industry plays significant role globally, supplying affordable and low-cost generic drugs to millions of people across the globe. The sector offers lower cost without compromising on quality as is reflected by the fact India has the highest number of United States Food and Drug Administration (USFDA) approved pharmaceutical plants outside the US and also a significant number of World Health Organization (WHO) Good Manufacturing Practices (GMP)-compliant plants as well as plants approved by regulatory authority of other countries. India accounts for 60 percent of global vaccine production, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette–Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine. There are 500 API manufacturers contributing about 8% in the global API Industry. India is the largest supplier of generic medicines and manufactures about 60,000 different generic brands across 60 therapeutic categories and accounts for 20% of the global supply of generics. Because of the low price and high quality, Indian medicines are preferred worldwide, making it “Pharmacy of the World”. India’s pharmaceutical sector forms a major component of the country’s foreign trade and has been consistently making trade surplus. The Government has put in place an investor-friendly Foreign Direct Investment (FDI) policy to promote investment in the Sector. In pharmaceuticals, up to 100% FDI in greenfield projects and up to 74% FDI in brownfield projects is allowed under the automatic route. The booming pharmaceutical industry of India is largely driven by cost-effective innovation when it comes to mass production of life saving drugs that are used by countries globally. During the Covid-19 pandemic, India was at the forefront of delivering essential drugs and vaccines to several nations. India’s With the immense potential for growth, pharmaceuticals sector is set to attain new heights in a post-pandemic world and elevate its position on the value chain by delivering affordable and quality-assured medicines and addressing the unmet needs of patients across the globe.


Social Network